Sugi Predict

Sugi Predict / Compounds / SCHEMBL21528098

SCHEMBL21528098

SCHEMBL21528098

O=C(O)CCOCCOCCOCCOCCN1C[C@@H]2C[C@H]1CN2CCOCCOCCNC(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ HTT P42858 1/20 0.51
▸ FOLH1 Q04609 5/20 0.46
▸ CPB1 P15086 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ TLR2 O60603 1/20 0.41
▸ TLR1 Q15399 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ KAT2B Q92831 1/20 0.40
▸ EPOR P19235 1/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ DPP7 Q9UHL4 1/20 0.40
▸ SLC1A3 P43003 1/20 0.40
▸ SLC1A1 P43005 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21528109 0.88 LMNA (0.52) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL16295008 0.84 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL18886394 0.84 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL18886422 0.84 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL31097862 0.84 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL30783527 0.84 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL30805590 0.84 LMNA (0.50) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL21527977 0.84 LMNA (0.66) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL24383283 0.83 SMN1; SMN2 (0.85) LMNASMN1; SMN2HTTFOLH1CPB1
SCHEMBL21528073 0.83 LMNA (0.51) LMNASMN1; SMN2HTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 — — US disclosed
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-03 — — US disclosed
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2025-01-07 — — US disclosed
EP-3788050-B1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2024-08-28 — — EP disclosed
CN-112771054-B C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-08-16 — — CN disclosed
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2024-07-30 — — US disclosed
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-23 — — US disclosed
CN-112368289-B C26-linked rapamycin analogues as MTOR inhibitors 锐新医药公司 2024-02-20 — — CN disclosed
EP-4234031-A2 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2023-08-30 — — EP disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2023-06-27 — — US disclosed
EP-3788049-B1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2023-03-29 — — EP disclosed
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-02-23 — — US disclosed
US-20220340596-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-10-27 — — US disclosed
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 — — US disclosed
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-11-04 — — US disclosed
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2021-04-20 — — US disclosed
EP-3788049-A1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
EP-3788050-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Revolution Medicines, Inc. 2019-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885HTT 898/4885
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885HTT 898/4885
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885HTT 898/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR LMNA 1680/4885SMN1; SMN2 1139/4885HTT 1473/4885
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-20220340596-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885HTT 898/4885
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885HTT 1420/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 LMNA 2304/4885SMN1; SMN2 1662/4885HTT 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.